BIOMARKER AND THERAPY INTERVENTION FOR MALIGNANCY RISK PATIENTS

The invention relates to a method of determining an increased risk of cancer in an immunosuppressed patient, the method comprising: (a) determining the percentage of CD8+CD57+ T-cells in a population of CD8+ T-cells in a sample from the patient; wherein a percentage of 40% or greater of CD8+CD57+ T-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BOTTOMLEY, MATTHEW JAMES, HARDEN, PAUL NEIL, WOOD, KATHYRN JAYNE
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BOTTOMLEY, MATTHEW JAMES
HARDEN, PAUL NEIL
WOOD, KATHYRN JAYNE
description The invention relates to a method of determining an increased risk of cancer in an immunosuppressed patient, the method comprising: (a) determining the percentage of CD8+CD57+ T-cells in a population of CD8+ T-cells in a sample from the patient; wherein a percentage of 40% or greater of CD8+CD57+ T-cells is indicative of an increased risk of cancer; and/or (b) determining the percentage of CD4+CD57+ T-cells in a population of CD4+ T-cells in a sample from the patient; wherein a percentage of 10% or greater of CD4+CD57+ T-cells is indicative of an increased risk of cancer. L'invention concerne une méthode de détermination d'un risque accru de cancer chez un patient immunodéprimé, la méthode consistant à : (a) déterminer le pourcentage de lymphocytes T CD8+CD57+ dans une population de lymphocytes T CD8+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 40 % de lymphocytes T CD8+CD57+ indiquant un risque accru de cancer ; et/ou (b) déterminer le pourcentage de lymphocytes T CD4+CD57+ dans une population de lymphocytes T CD4+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 10 % de lymphocytes T CD4+CD57+ indiquant un risque accru de cancer.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2016063075A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2016063075A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2016063075A13</originalsourceid><addsrcrecordid>eNrjZLB38vT3dQzydg1ScPRzUQjxcA1yDIhU8PQLcQ0Kc_UL8fT3U3DzD1LwdfTxdPdz9HOOVAjyDPZWCHAM8QRKB_MwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDQzMDM2MDc1NHQ2PiVAEASKUrjg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BIOMARKER AND THERAPY INTERVENTION FOR MALIGNANCY RISK PATIENTS</title><source>esp@cenet</source><creator>BOTTOMLEY, MATTHEW JAMES ; HARDEN, PAUL NEIL ; WOOD, KATHYRN JAYNE</creator><creatorcontrib>BOTTOMLEY, MATTHEW JAMES ; HARDEN, PAUL NEIL ; WOOD, KATHYRN JAYNE</creatorcontrib><description>The invention relates to a method of determining an increased risk of cancer in an immunosuppressed patient, the method comprising: (a) determining the percentage of CD8+CD57+ T-cells in a population of CD8+ T-cells in a sample from the patient; wherein a percentage of 40% or greater of CD8+CD57+ T-cells is indicative of an increased risk of cancer; and/or (b) determining the percentage of CD4+CD57+ T-cells in a population of CD4+ T-cells in a sample from the patient; wherein a percentage of 10% or greater of CD4+CD57+ T-cells is indicative of an increased risk of cancer. L'invention concerne une méthode de détermination d'un risque accru de cancer chez un patient immunodéprimé, la méthode consistant à : (a) déterminer le pourcentage de lymphocytes T CD8+CD57+ dans une population de lymphocytes T CD8+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 40 % de lymphocytes T CD8+CD57+ indiquant un risque accru de cancer ; et/ou (b) déterminer le pourcentage de lymphocytes T CD4+CD57+ dans une population de lymphocytes T CD4+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 10 % de lymphocytes T CD4+CD57+ indiquant un risque accru de cancer.</description><language>eng ; fre</language><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; PHYSICS ; TESTING</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20160428&amp;DB=EPODOC&amp;CC=WO&amp;NR=2016063075A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20160428&amp;DB=EPODOC&amp;CC=WO&amp;NR=2016063075A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BOTTOMLEY, MATTHEW JAMES</creatorcontrib><creatorcontrib>HARDEN, PAUL NEIL</creatorcontrib><creatorcontrib>WOOD, KATHYRN JAYNE</creatorcontrib><title>BIOMARKER AND THERAPY INTERVENTION FOR MALIGNANCY RISK PATIENTS</title><description>The invention relates to a method of determining an increased risk of cancer in an immunosuppressed patient, the method comprising: (a) determining the percentage of CD8+CD57+ T-cells in a population of CD8+ T-cells in a sample from the patient; wherein a percentage of 40% or greater of CD8+CD57+ T-cells is indicative of an increased risk of cancer; and/or (b) determining the percentage of CD4+CD57+ T-cells in a population of CD4+ T-cells in a sample from the patient; wherein a percentage of 10% or greater of CD4+CD57+ T-cells is indicative of an increased risk of cancer. L'invention concerne une méthode de détermination d'un risque accru de cancer chez un patient immunodéprimé, la méthode consistant à : (a) déterminer le pourcentage de lymphocytes T CD8+CD57+ dans une population de lymphocytes T CD8+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 40 % de lymphocytes T CD8+CD57+ indiquant un risque accru de cancer ; et/ou (b) déterminer le pourcentage de lymphocytes T CD4+CD57+ dans une population de lymphocytes T CD4+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 10 % de lymphocytes T CD4+CD57+ indiquant un risque accru de cancer.</description><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>PHYSICS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB38vT3dQzydg1ScPRzUQjxcA1yDIhU8PQLcQ0Kc_UL8fT3U3DzD1LwdfTxdPdz9HOOVAjyDPZWCHAM8QRKB_MwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDQzMDM2MDc1NHQ2PiVAEASKUrjg</recordid><startdate>20160428</startdate><enddate>20160428</enddate><creator>BOTTOMLEY, MATTHEW JAMES</creator><creator>HARDEN, PAUL NEIL</creator><creator>WOOD, KATHYRN JAYNE</creator><scope>EVB</scope></search><sort><creationdate>20160428</creationdate><title>BIOMARKER AND THERAPY INTERVENTION FOR MALIGNANCY RISK PATIENTS</title><author>BOTTOMLEY, MATTHEW JAMES ; HARDEN, PAUL NEIL ; WOOD, KATHYRN JAYNE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2016063075A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2016</creationdate><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>PHYSICS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>BOTTOMLEY, MATTHEW JAMES</creatorcontrib><creatorcontrib>HARDEN, PAUL NEIL</creatorcontrib><creatorcontrib>WOOD, KATHYRN JAYNE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BOTTOMLEY, MATTHEW JAMES</au><au>HARDEN, PAUL NEIL</au><au>WOOD, KATHYRN JAYNE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BIOMARKER AND THERAPY INTERVENTION FOR MALIGNANCY RISK PATIENTS</title><date>2016-04-28</date><risdate>2016</risdate><abstract>The invention relates to a method of determining an increased risk of cancer in an immunosuppressed patient, the method comprising: (a) determining the percentage of CD8+CD57+ T-cells in a population of CD8+ T-cells in a sample from the patient; wherein a percentage of 40% or greater of CD8+CD57+ T-cells is indicative of an increased risk of cancer; and/or (b) determining the percentage of CD4+CD57+ T-cells in a population of CD4+ T-cells in a sample from the patient; wherein a percentage of 10% or greater of CD4+CD57+ T-cells is indicative of an increased risk of cancer. L'invention concerne une méthode de détermination d'un risque accru de cancer chez un patient immunodéprimé, la méthode consistant à : (a) déterminer le pourcentage de lymphocytes T CD8+CD57+ dans une population de lymphocytes T CD8+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 40 % de lymphocytes T CD8+CD57+ indiquant un risque accru de cancer ; et/ou (b) déterminer le pourcentage de lymphocytes T CD4+CD57+ dans une population de lymphocytes T CD4+ dans un échantillon provenant du patient ; un pourcentage supérieur ou égal à 10 % de lymphocytes T CD4+CD57+ indiquant un risque accru de cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2016063075A1
source esp@cenet
subjects INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
PHYSICS
TESTING
title BIOMARKER AND THERAPY INTERVENTION FOR MALIGNANCY RISK PATIENTS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T11%3A53%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BOTTOMLEY,%20MATTHEW%20JAMES&rft.date=2016-04-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2016063075A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true